Immunome IMNM
NASDAQ IMNM
$20.90 +0.01 (+0.05%)
At close: Oct 2, 2026 · 4:00 PM EDT

Immunome (IMNM) Price to Sales (2023 - 2026)

Updated

Immunome's (IMNM) Price to Sales came in at 616.45 for Q1 2026, compared with 53.50 a year earlier and up 128.0% from the prior quarter.

Analysis

Immunome (IMNM) Price to Sales (2023 - 2026) Analysis & Trends

For FY2025, Immunome's Price to Sales stood at 270.32, up 257.0% from FY2024.

  • In prior years, Immunome's Price to Sales was 75.72 in FY2024 (+399.9%) and 15.15 in FY2023.
  • The Q1 2026 figure stands as the highest quarterly Price to Sales in data going back to Q4 2023.
  • On a year-over-year basis, Price to Sales increased in three of the last five quarters, with growth averaging 125.1%.
  • According to Business Quant data, Price to Sales for the three prior quarters was 270.32 (Q4 2025), 110.95 (Q3 2025) and 64.28 (Q2 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn
10 Immunome 2.37 Bn 340.08 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 616.45
Dec 31, 2025 270.32
Sep 30, 2025 110.95
Jun 30, 2025 64.28
Mar 31, 2025 53.50
Dec 31, 2024 75.72
Sep 30, 2024 87.21
Jun 30, 2024 67.34
Mar 31, 2024 116.16
Dec 31, 2023 15.15
API Access

Immunome Price to Sales API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-sales&ticker=IMNM&period=max&api_key=YOUR_API_KEY